Screening method for inhibiting angiogenesis targets through celecoxib

A technology of celecoxib and angiogenesis, applied in bioinformatics, used to analyze two-dimensional or three-dimensional molecular structures, instruments, etc., can solve the problem of lack of COX-2-independent biomarkers, weak tumor inhibition, loss of And other issues

Inactive Publication Date: 2018-07-13
ARMY MEDICAL UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is generally believed that celecoxib inhibits the synthesis of prostaglandin PGE2 by inhibiting the activity of COX-2, thereby blocking tumor growth; Rofecoxib, more potent at inhibiting COX-2 but less potent at suppressing tumors
At the same time, adding a methyl group to celecoxib, 2,5-dimethyl-celecoxib (DMC), lost the ability to inhibit COX-2, but it can almost completely mimic the tumor suppressor function of celecoxib
In addition, the randomized controlled study of Celecoxib concurrent radiotherapy for lung cancer resulted in negative results due to failure to complete the expected enrollment. The important reason is the lack of COX-2-independent biomarkers and selective inclusion of subjects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Screening method for inhibiting angiogenesis targets through celecoxib
  • Screening method for inhibiting angiogenesis targets through celecoxib
  • Screening method for inhibiting angiogenesis targets through celecoxib

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] 1. Screen protein

[0023] Select angiogenesis PCR chip including ANG, ANGPT1, ANGPT2, ANPEP, TYMP, FGF1, FGF2 (bFGF), FIGF (VEGFD), FLT1, JAG1, KDR, NRP1, NRP2, PGF, VEGFA, VEGFB, VEGFC, BAI1, COL4A3 , IL8, ANGPTL4, F3, PECAM1, PF4, PROK2, SERPINE1(PAI-1), SERPINF1, HIF1A, NOS3, SPHK1, CCL11(Eotaxin), CCL2(MCP-1), CXCL1, CXCL10(INP10), CXCL5(ENA78 / LIX), CXCL6(GCP-2), CXCL9(MIG), EDN1, IFNA1, IFNG, IL1B, IL6, MDK, TNF, CTGF, EFNA1, EFNB2, EGF, EPHB4, FGFR3, HGF, IGF1, ITGB3, PDGFA, S1PR1 , TEK(TIE2), TGFA, TGFB1, TGFB2, TGFBR1, CDH5, COL18A1, ENG(EVI-1), ERBB2(HER2), FN1, ITGAV, ITGB3, THBS1, THBS2, LECT1, LEP, MMP14, MMP2, MMP9, Proteins expressed by 84 genes including PLAU(uPA), PLG, TIMP1, TIMP2, TIMP3, AKT1, PTGS1, PTGS2, MMP1, MMP3 are used as potential receptor protein database. After searching the structure of each protein in PDB and UniProt protein structure database, the resolution of X-ray crystal structure was selected in NMR structural resolution For ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of treating tumor diseases, and particularly relates to a screening method for inhibiting angiogenesis targets through celecoxib. According to the method, by selecting protein expressed by 84 genes on a blood vessel formation polymerase chain reaction chip as a potential receptor protein database (PDB), the PDB and a UniProt database are used for screening 54 receptor protein structures, MGLTools is used for processing the receptor protein structures, after a molecular docking box is constructed, Autodock_vina is used as a molecular docking tool to calculatethe free energy of the binding site of the celecoxib and each protein receptor, and the protein receptors with the binding site free energy smaller than 9.0 kcal / mol are selected as potential targets.

Description

technical field [0001] The invention belongs to the field of treating tumor diseases, and in particular relates to a screening method for celecoxib to inhibit angiogenesis targets. Background technique [0002] Celecoxib has been reported to promote cell apoptosis and inhibit angiogenesis, thereby inhibiting tumor growth. Its anti-angiogenic effect is generally considered to be related to the inhibition of cyclooxygenase-2 (COX-2) activity. However, our previous studies found that different concentrations of celecoxib could not block the increase of COX-2 activity after radiotherapy. Therefore, celecoxib may inhibit angiogenesis through a COX-2-independent pathway, that is, an off-target effect (Off- target) to achieve. Recent studies support our finding that there is a COX-2-independent pathway for the antitumor effect of celecoxib. It is generally believed that celecoxib inhibits the synthesis of prostaglandin PGE2 by inhibiting the activity of COX-2, thereby blocking t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G06F19/16
CPCG16B15/00
Inventor 谌谐婉孙建国牛凯廖荣霞
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap